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ABSTRACT
Human carbonic anhydrase (CA) IX has emerged as a promising anticancer 
target and a diagnostic biomarker for solid hypoxic tumors. Novel fluorinated CA 
IX inhibitors exhibited up to 50 pM affinity towards the recombinant human CA IX, 
selectivity over other CAs, and direct binding to Zn(II) in the active site of CA IX 
inducing novel conformational changes as determined by X-ray crystallography. Mass 
spectrometric gas-analysis confirmed the CA IX-based mechanism of the inhibitors in 
a CRISPR/Cas9-mediated CA IX knockout in HeLa cells. Hypoxia-induced extracellular 
acidification was significantly reduced in HeLa, H460, MDA-MB-231, and A549 cells 
exposed to the compounds, with the IC50 values up to 1.29 nM. A decreased clonogenic 
survival was observed when hypoxic H460 3D spheroids were incubated with our 
lead compound. These novel compounds are therefore promising agents for CA IX-
specific therapy.
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INTRODUCTION
Tumor hypoxia promotes invasiveness and is 
associated with resistance to chemotherapeutics and 
radiation and thus poor prognosis [1–5]. Human carbonic 
anhydrase IX (CA IX) shows limited expression in normal 
tissues [6] and is significantly up-regulated by hypoxia-
inducible factor 1α (HIF-1α) [7] or other alternative 
microenvironmental factors [8–12] in a variety of 
tumors. CA IX is crucial for cancer cell survival because 
bicarbonate and protons, produced upon CA IX-catalyzed 
reversible hydration of CO2, are necessary to maintain the 
cellular pH balance: bicarbonate is transported into the 
cell to neutralize intracellular acid, while protons increase 
extracellular acidification [13–16]. CA IX also stimulates 
cell spreading and epithelial-mesenchymal transition 
[17, 18]. Therefore, CA IX has been proposed to be a 
promising tumor hypoxia biomarker for diagnostic and 
targeted drug delivery applications [19].
Sulfonamides are classical CA inhibitors, where 
the deprotonated sulfonamide group is required 
for displacement of the catalytic Zn2+-bound water 
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molecule to bind directly with Zn2+ in the active site 
to inhibit CA [20, 21]. Therefore, the binding affinity 
can be enhanced using inhibitors with the lowered 
pKa of the sulfonamide group [21, 22]. Introduction of 
fluorine atoms that lower the pKa due to their electron-
withdrawing capabilities is one of the choices due to 
unique features, such as high electronegativity, small 
size, low atomic weight, and contribution to increased 
lipophilicity. Fluorine is found in ~20% of current 
pharmaceuticals and this trend is increasing [23]. 
Krishnamurthy and colleagues investigated fluorinated 
benzensulfonamides and concluded that fluorine is the 
best choice for electron-withdrawing substituents [21]. 
We expanded this strategy and created new routes for 
functionalization of pentafluorobenzensulfonamides 
[24, 25] including para-, ortho-, and meta- substituted 
fluorinated benzensulfonamides. The bulky hydrophobic 
groups at ortho or meta positions are necessary for the 
favorable hydrophobic contacts with the amino acids of 
CA IX binding pocket [26]. Here we present novel the 
ortho-substituted fluorinated benzenesulfonamides VR16-
09 and VR16-10 (Table 1, Scheme 1) in combination with 
the previously chemically and biophysically characterized 
meta and ortho-substituted fluorinated inhibitors VD11-
4-2 and VD12-09 [26]. We hypothesized that these 
benzenesulfonamides will exhibit high affinity and 
strong selectivity towards recombinant CA IX and will 
possess significant functional effects in cancer cell lines 
on reducing hypoxia-induced acidosis as well as hypoxia-
dependent clonogenic survival, providing efficacious 
opportunity to target CA IX-expressing cells.
RESULTS AND DISCUSSION
Binding and inhibition of recombinant CA 
isoforms
The affinities of VR16-09 and VR16-10 to 12 
catalytically active recombinant CA isoforms were 
determined by the fluorescent thermal-shift assay (FTSA) 
and compared with previously published [26] inhibitors 
VD11-4-2 and VD12-09 (Table 1). The Ki values against 
CA IX and CA XII were also measured by the stopped-
flow inhibition assay (SFA) of the CO2 hydration CA 
enzymatic activity (Table 1). FTSA revealed that VR16-
09 bound CA IX significantly (Kd = 0.16 nM) stronger 
than other CA isoforms (Kds > 200 µM) (Table 1, Figure 
1A–1C). VR16-09 with the bulky aminocyclododecyl 
group exhibited greater selectivity towards CA IX as 
compared with VR16-10, VD12-09, and VD11-4-2 
bearing aminocyclooctyl groups. SFA did not allow the 
determination of Ki < ~2 nM against CA IX, because 
the concentration of CA IX was 10 nM, thus limiting 
the determination of IC50 at 5 nM. Therefore, the Kds 
determined by the FTSA should be used rather than SFA. 
Nevertheless, SFA confirmed that VR16-09 and VR16-10 
efficiently inhibited the CA IX activity (Figure 1D–1F). 
These compounds are advantageous compared to SLC-
0111 that has entered the clinical trials (Ki(CA IX) = 45 nM, 
Ki(CA XII) = 4.5 nM and only 20-fold selectivity over CA 
II, thus would possibly exhibit larger adverse effects [27, 
28]). In contrast, selectivity of VR16-09 for CA IX over 
CA I and CA II is more than one million-fold.
Crystal structures of inhibitors bound to 
recombinant CA IX
The structures of the CA IX catalytic domain 
in complex with VR16-09 (PDB ID: 6G98), VR16-
10 (PDB ID: 6G9U), VD12-09 (PDB ID: 6FE0) and 
VD11-4-2 (PDB ID: 6FE1) were determined by X-ray 
crystallography at resolutions ranging from 1.75 Å to 2.47 
Å (Figure 2, Supplementary Table 1). The sulfonamide 
moiety and trifluorobenzene cycle of all observed 
ligands fit in the conserved region of the CA IX active 
site, the cycloalkane tail moieties were guided towards 
the hydrophobic part of the active site and moieties with 
terminal hydroxyl group were located in the hydrophilic 
part of the active site. The sulfonamide amino group 
formed a coordination bond with Zn(II), as observed 
in many other CA-sulfonamide complexes. All ligands 
were positioned very similarly within the active site of 
CA IX, except with some differences occurring in the 
case of VD11-4-2 (Figure 2). VD11-4-2 also formed 
two additional hydrogen bonds with Asn62 and Gln92, 
which might explain its stronger affinity for CA IX as 
compared to other analyzed compounds. All four crystal 
structures showed that some conformational changes have 
occurred in the CA IX active site pocket as compared 
to other known CA IX structures [29, 30]. In order to 
fully understand conformational changes occurring in 
those cases, we also determined apo (ligand free) CA IX 
structure at 1.87 Å resolution (PDB ID: 6FE2). In case 
of VR16-09, the cyclododecyl moiety altered rotamer of 
Gln92, which in turn changed the conformation of Gln67 
(Figure 2).
CA IX-dependent functional activities of 
inhibitors in cancer cells
Compounds were evaluated for their biological 
functional activities in a panel of human cancer cell 
lines. CA IX expression was increased in hypoxic (0.2% 
O2) A549 (lung), AsPC-1 (pancreatic), MDA-MB-231 
(breast), H460 (lung), and HeLa (cervical) cancer cells, 
whereas CA XII expression was similar under normoxia 
and hypoxia (Supplementary Figures 1, 2). We evaluated 
the potency of the compounds to inhibit the CA catalytic 
activity in hypoxic MDA-MB-231 cells by determining 
the rate of the CO2/HCO3
- hydration/dehydration 
reaction via 18O depletion from 13C18O2, measured by 
mass-spectrometric (MS) gas analysis. Addition of cell 
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suspension resulted in an acceleration of the reaction, 
indicating CA catalytic activity in MDA-MB-231 cells 
(Figure 3A). Pre-incubation of the cell suspension with 
VR16-09, VD11-4-2, or VD12-09 resulted in a dose-
dependent decrease in CA activity (Figure 3B–3D). 
To verify the CA IX specificity, hypoxic HeLa cells, in 
which CA IX was knocked out (KO) (Supplementary 
Figure 3), were exposed to VR16-09, VD11-4-2 and 
VD12-09 at concentrations of near maximum inhibition 
of extracellular CA activity in hypoxic MDA-MB-231 
cells. In both HeLa CA IX KO lines, VR16-09 (300 nM), 
VD11-4-2 (300 nM), or VD12-09 (30 µM) did not alter 
CA activity (Figure 3E), although considerable CA activity 
remained, indicating activity of other CA isoforms. In 
HeLa wild-type (WT) cells, CA activity decreased (P < 
0.01) to 30–40%, values that did not significantly differ 
from the two HeLa CA IX KO cell lines. Thus, VR16-
09, VD11-4-2, and VD12-09 specifically target CA IX, 
while other CAs remain unaffected. Previously Frost 
and colleagues reported a Ki value of 85.3 nM against 
extracellular CA for the fluorescent sulfonamide Cpd 5c 
in intact hypoxic MDA-MB-231 cells using the same 18O 
exchange assay [31]. Extracellular CA activity of MDA-
MB-231 cells was also significantly reduced by 1 µM 
acetazolamide [32]. The inhibitors VR16-09 and VD11-
4-2 exhibited higher effect towards CA IX expressed in 
cellular models than previously reported compounds likely 
due to higher affinity.
The functional activity of inhibitors was further 
confirmed by measuring the rise in extracellular pH 
directly inside a hypoxic chamber [33]. VR16-09, VD11-
4-2, and VD12-09 significantly (p < 0.05) reduced 
hypoxia-induced acidification of HeLa cells in a dose-
dependent manner, while the effect on cells exposed to 
normoxia was negligible (Figure 4A). This functional 
activity was the most pronounced for VR16-09 at 50 
µM, which significantly reduced hypoxia-induced 
acidosis of 4 investigated cell lines (Figure 4A, 4B). 
VD11-4-2 also significantly reduced (p < 0.05) hypoxic 
acidification of HeLa, H460, MDA-MB-231, and A549 
cells (Figure 4A, 4C). A 4-fold lower concentration of 
sodium bicarbonate in the medium was used for A549 
to determine the functional effects of the compounds 
due to relatively low levels of hypoxia-induced CA IX 
Table 1: The dissociation constants (Kds) of VR16-09, VR16-10, VD11-4-2, and VD12-09 for 12 recombinant catalytic 
domains of human active CA isoforms as determined by FTSA at pH 7.0 (37° C)
CA isoform
Kd (Ki), nM
VR16-09
SO2NH2
S
COOH
N
H
F
F F
VR16-10
SO2NH2
S
COOH
N
H
F
F F
VD11-4-2*
SO2NH2
N
H
SO2
FF
F
OH
VD12-09*
SO2NH2
S
N
H
F
F
OH
F
CA I ≥200 000 5000 710 50 000
CA II ≥200 000 1000 60 1 300
CA III ≥200 000 ≥200 000 40 000 ≥200 000
CA IV ≥200 000 1820 25 1 700
CA VA ≥200 000 5000 2 500 3 300
CA VB 45000 100 5.6 210
CA VI ≥200 000 26300 95 4 300
CA VII 37 000 100 9.8 330
CA IX 0.16 (<1) 0.20 (<1) 0.05 1.1
CA XII 710 (100) 370 3.3 330
CA XIII 20 40 3.6 140
CA XIV 170 170 1.6 170
The Ki values determined by SFA (pH 7.5, 25°
 C) are shown in the parentheses. Uncertainties of FTSA and SFA 
measurements do not exceed 2-fold.
*Kd values of VD11-4-2 and VD12-09 towards CA isoforms have been already published [26].
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Scheme 1: Synthesis scheme of VR16-09 and VR16-10. Reagents and conditions: (a) NH3 aq, THF, –10° C; (b) 7, Et3N, MeOH, 
r.t. 24 h, then conc. HCl; (c1) cyclododecylamine, Et3N, DMSO, 70° C, 36 h, then H2O, HCl; (c2) cyclooctylamine, Et3N, DMSO, 70° C, 
24 h, then H2O, HCl; (d) CH3COCl, AlCl3, CH2Cl2, 0° C – +2° C, then conc. HCl; (e) NaOH, H2O, dioxane, Br2, 0° C – +2° C, then conc. 
HCl, (f) NH2CSNH2, H2O, reflux 3 h, then NaOH 1 h reflux, then 2M HCl.
Figure 1: The binding affinity by FTSA (panels A–C) and inhibition by SFA (panels D–F) of VR16-09 towards human recombinant CAs. 
Thermal melting curves of 8 μM CA IX (A) and 5 μM CA II (B) determined by ANS fluorescence in the presence of various VR16-09 
concentrations. (C) Melting temperatures (Tm) of CA IX (■), CA II (◊) and CA XII (▲) as a function of added compound concentration. 
The lines were regressed according to [60]. Absorbance decrease due to enzymatic acidification of the medium by CA IX (D) or CA XII (E) 
for various VR16-09 concentrations. (F) Fraction inhibition of CA IX (■) or CA XII (▲) as a function of the total VR16-09 concentration. 
The lines are fit according to the Morrison equation [50].
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(Supplementary Figure 1). VD12-09 exhibited functional 
activity in HeLa cells (Figure 4A). The smallest, albeit 
significant (p < 0.05), impact on extracellular acidification 
was found for VR16-10 (Supplementary Figure 4). 
Interestingly, inhibitors VR16-09 and VR16-10 differ 
structurally by the size of the hydrophobic ring at ortho 
position. Thus, a 12-carbon ring of VR16-09 was found 
to be more favorable than an 8-carbon ring of VR16-10 
because ~3-fold higher functional effects of VR16-09 on 
the reduction of hypoxia-induced acidification of H460 
cells were observed, even though their affinities towards 
recombinant CA IX were similar (Kds of 0.16 and 0.20 
nM, respectively). Functional activities of several CA 
IX-targeting agents, such as fluorescent sulfonamide [33] 
and nitroimidazole-based inhibitors [34, 35] have been 
previously reported using the same method in HeLa cells, 
where a dose-dependent reduction in hypoxia-induced 
extracellular acidification was observed. Results of the 
current study indicate that the inhibitors investigated 
here are more efficacious in decreasing extracellular 
acidification than previously described compounds 
because of their significant functionality at lower 
concentrations (5–50 µM), highlighting the potential for 
CA IX-targeting therapy.
Interestingly, hypoxia-induced acidosis of AsPC-
1 cells increased after exposure to VR16-09 or VD11-
4-2 (Figure 4B, 4C), related to the unique expression 
of monocarboxylate transporter 1 (MCT1) under 
both normoxic and hypoxic conditions in these cells 
(Supplementary Figure 5A). Recently, CA IX was 
Figure 2: Crystal structure of VR16-09 (panel A, PDB ID: 6G98) bound in the active site of human recombinant CA IX. The Fo − Fc omit 
map is contoured at 3σ. (Panel B) shows that VR16-09 fitted in apo-CA IX structure (PDB ID: 6FE2), demonstrating collision points with 
residues indicating too short inter-atomic distances if conformational changes had not occurred. Protein and ligand carbons are shown in 
green and black, respectively, and apo-CA IX residues are shown in light blue. Atom colors are: oxygen (red), nitrogen (blue), fluorine 
(light blue), and sulfur (yellow). (Panel C) shows comparison of binding modes for compounds VR16-09 (black carbons), VR16-10 (green 
carbons), VD12-09 (yellow carbons), and VD11-4-2 (light blue carbons). The zinc ion is shown as a gray sphere and residues participating 
in hydrogen bonds or charged interactions are also specified for the respective inhibitors. The figure was prepared using Pymol [61].
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Figure 3: IC50 determination of VR16-09, VD11-4-2, and VD12-09 in hypoxic MDA-MB-231 cells and CA IX-dependent 
mode of action for inhibitors in hypoxic HeLa CA IX KO cells. (A) Original recordings of the log enrichment of MDA-MB-231 
cells pre-incubated with VD11-4-2 for up to 3 h. The beginning of each trace shows the rate of degradation of the 18O-labeled substrate 
in the non-catalyzed reaction. (B–D) – Relative CA activity in MDA-MB-231 cells, incubated under hypoxia (1% O2) for 3 days. Cells 
were pre-incubated with VR16-09 (B), VD11-4-2 (C), or VD12-09 (D) for up to 3 h. CA activity was determined by MS gas-analysis from 
the increase in the rate of log enrichment after addition of cell suspension. CA activity in the presence of inhibitor was normalized to the 
activity in the absence of inhibitor. (E) CA activity in HeLa-WT and HeLa-CA IX-KO cells, before (white bars) and after addition of VR16-
09, VD11-4-2 or VD12-09 (black bars). Average + SD of 4 independent experiments per cell line are shown. Asterisks indicate significant 
difference between CA activity before and after addition of inhibitor (**p < 0.01, ***p < 0.001, n.s.: not significant).
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proposed to be a ‘H+-distributing antenna’ for MCT1 
to facilitate rapid extrusion of lactate and H+ from the 
cell [36]. Even though the catalytic activity of CA IX 
was inhibited in AsPC-1 by compounds, the rise of 
acidification might be caused by MCT1 which is further 
non-catalytically stimulated by CA IX. In contrast, MCT4 
was expressed in all tested cell lines and was up-regulated 
in response to hypoxia (Supplementary Figure 5B), in line 
with previously confirmed HIF-1α-dependent mechanism 
of MCT4 expression in cancer cells [37]. 
Inhibitor-induced cytotoxicity 
Cytotoxicity of tested compounds was higher in 
normoxic than hypoxic cell monolayers, as determined by 
cell viability assay using alamarBlue® after treatment for 48 
Figure 4: (A) Changes in extracellular acidification of HeLa cells after the treatment with VR16-09, VD11-4-2 or VD12-09 for 72 h under 
normoxia (21% O2; white bars) or hypoxia (0.2% O2; grey bars). (B–C) Effect of VR16-09 (B) and VD11-4-2 (C) on the hypoxia-induced 
extracellular acidification of H460, MDA-MB-231, A549, and AsPC-1 after the exposure for 72 h. Average ± SD of at least 3 independent 
experiments is shown. Asterisks indicate significant difference between medium pH of cells exposed to DMSO and cells treated with 
various doses of inhibitor under hypoxic conditions (*p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001).
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h or 72 h (Supplementary Figure 6A, 6B, Supplementary 
Table 2). Inhibitors were less effective in reducing viability 
of hypoxic CA IX-expressing cells than normoxic cells 
without or with significantly lower CA IX expression. 
Sensitivity of HeLa and H460 cells to VR16-10 was the 
lowest and is in line with the lowest VR16-10 functional 
activity measured by extracellular pH assay. Therefore, 
VR16-10 was not investigated further. Similarly, 
compounds were more effective in reducing clonogenic 
survival in normoxic compared to hypoxic monolayer 
HeLa cells (Supplementary Figure 6C). Our results 
correlate with previously published cytotoxicity profiles of 
benzenesulfonamides, including SLC-0111 [38], sulfamate 
S4 [39], and dual-target compounds bearing various CA IX-
targeting moieties combined with different anti-cancer drugs 
[40], which showed more effective cell kill in normoxia 
than hypoxia. We hypothesize that higher cytotoxicity of 
inhibitors in normoxic cells as compared with hypoxic 
cells could be due to the affinity of investigated compounds 
towards CA XII, expressed in all cell lines investigated here 
and shown to be up-regulated to compensate the CA IX 
knockdown [41]. Thus, new cellular models with both CA 
IX and CA XII KO would be crucial to determine the link 
between functional activity of compounds and CA IX or CA 
XII-dependent cellular mechanisms.
Hypoxia-dependent effect on spheroid clonogenic 
survival
To confirm the CA IX-dependent efficacy of 
the compounds, H460 spheroids were employed. 
Immunofluorescence analysis confirmed overlap between 
CA IX expression and pimonidazole (PIMO)-positive 
hypoxia in sections of H460 spheroids grown for 11 
days, whereas neither CA IX nor hypoxia were found in 
spheroids grown for 7 days (Figure 5A). Therefore, non-
hypoxic (4 days) and hypoxic (11 days) H460 spheroids 
were exposed to VR16-09 using an effective dose based 
on extracellular pH assays (Figure 4A, 4B) for 24 h and 
afterwards plated for clonogenic survival. In contrast to 2D 
cell viability and clonogenic survival assays, a hypoxia-
dependent effect on clonogenic survival of VR16-09 was 
Figure 5: (A) Immunofluorescence images of H460 spheroids stained for DAPI (blue), PIMO (green) and CA IX (red). The scale bar 
indicates 100 µM. (B) Survival of clonogenic cells derived from non-hypoxic (■) and hypoxic (□) H460 spheroids exposed to VR16-09 for 
24 h on day 4 or day 11, respectively. Asterisks indicate statistically significant differences between the surviving fractions of clonogenic 
cells derived from normoxic or hypoxic spheroids after exposure to the same dose (*p < 0.05, ***p < 0.001).
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found in H460 spheroids (Figure 5B). The 3D cell models 
reflect important properties of in vivo tumors such as 
interactions between cells, oxygen gradients, penetration of 
drugs, response and resistance, and production/deposition 
of extracellular matrix, which are absent in rapidly and 
uncontrollably growing 2D cells [42–44]. Our study 
confirms the importance of using in vitro 3D cellular 
models for screening of CA IX-targeting inhibitors. 
MATERIALS AND METHODS
Chemistry
VR16-09 and VR16-10 were synthesized following 
a similar route as described in our previous research [24]. 
Pentafluorobenzenesulfonyl chloride (1, Acros Organics) 
was converted to pentafluorobenzenesulfonamide 
(2) via amination with aqueous ammonia (scheme 
1) by our improved method [25]. On the basis of our 
previous investigations, sulfonamide 2 undergoes 
aromatic nucleophilic substitution reactions with sulfur-
centered nucleophiles readily and forms exclusively 
the para-substituted products. High reactivity of 
polyfluorinated compounds leads to the formation of 
monosubstituted or even further substituted compounds. 
The subsequent ortho-substitution occurs in the case of 
4-substituted-2,3,5,6-tetrafluobenzenesulfonamides, 
bearing non-oxidized sulfur-centered substitutes at 
para position. Similarly, sulfonamide 2 was treated 
with 4-(2-mercaptoethyl)benzoic acid (7) to furnish 
para-substituted compound 3 and subsequent 
aromatic nucleophilic substitution reactions with 
cyclododecylamine and cyclooctylamine in DMSO in the 
presence of Et3N yielded desirable compounds VR16-09 
and VR16-10. Since suitable sulfur-centered nucleophile 
7 was not commercially available, it was synthesized 
using literature methods. Starting from commercially 
available (2-bromoethyl)benzene (4, Acros Organics), 
Friedel-Crafts acylation with acetyl chloride proceeded in 
high yield. Acylation was accomplished as described in 
literature [45], except for changing highly toxic solvent 
carbon disulfide to more acceptable dichloromethane. 
Conversion of methyl ketone 5 into benzoic acid 6 
was carried out via haloform reaction by the method 
of Foreman and McElvain [46]. Finally, benzoic acid 6 
was treated with thiourea in refluxing water to generate 
intermediate salt, which was partitioned by adding sodium 
hydroxide solution as described by Takano [47].
Compound characterization
All starting materials and reagents were commercial 
products. They were used without further purification. 
Melting points of the compounds were determined in open 
capillaries on a Thermo Scientific 9100 Series and are 
uncorrected. 1H and 13C NMR spectra were recorded on 
a Bruker spectrometer (400 and 100 MHz, respectively) 
in DMSO-d6 using residual DMSO signals (2.52 ppm and 
40.21 ppm for 1H and 13C NMR spectra, respectively) 
as internal standard. 19F NMR spectra were recorded 
on a Bruker spectrometer (376 MHz) with CFCl3 as an 
internal standard. Proton, carbon and fluorine chemical 
shifts were expressed in parts per million (ppm) in the 
indicated solvent. Multiplicity was defined as s (singlet), d 
(doublet), t (triplet), q (quartet), dd (a doublet of doublets), 
ddd (a doublet of doublet of doublets), m (multiplet), br 
s (broad singlet). TLC was performed with silica gel 60 
F254 aluminum plates (Merck) and visualized with UV 
light. Column chromatography was performed using 
silica gel 60 (0.040–0.063 mm, Merck). High-resolution 
mass spectra (HRMS) were recorded on a Dual-ESI 
Q-TOF 6520 mass spectrometer (Agilent Technologies). 
The purity of final compounds was verified by HPLC to 
be >95% using the Agilent 1290 Infinity instrument with 
a Poroshell 120 SB-C18 (2.1 mm × 100 mm, 2.7 μm) 
reversed-phase column.
Pentafluorobenzenesulfonamide (2)
The solution of pentafluorobenzenesulfonyl chloride 
(1) (1.00 g, 3.75 mmol) and THF (60 mL) was cooled to 
~ –10° C and aqueous ammonia (~1.20 mL, 25 %) was 
added dropwise while stirring until the solution was at 
pH ~7. After stirring for an additional 1 h, the solvent 
was removed under reduced pressure and the white 
solid was washed with cold H2O. Recrystallization was 
accomplished from H2O. Yield: 0.84 g (90 %), mp 156–
157° C close to the value in the literature, mp 156° C [48]. 
1H NMR (400 MHz, DMSO-d6): 8.48 (2H, s, SO2NH2). 
19F NMR (376 MHz, DMSO-d6): –139.5 (2F, dd, 
1J = 19 
Hz, 2J = 6 Hz), –149.39 (1F, t, J = 22 Hz), –161.03 (2F, t, 
J = 20 Hz).
4-(2-{[4-(Aminosulfonyl)-2,3,5,6-
tetrafluorophenyl]thio}ethyl)benzoic acid (3)
The mixture of pentafluorobenzenesulfonamide (2) 
(2.00 g, 8.09 mmol), 4-(2-mercaptoethyl)benzoic acid 
(7) (1.77 g, 9.71 mmol), Et3N (2.50 mL, 17.9 mmol), and 
MeOH (20 mL) was stirred at ambient temperature for 24 
h. The solution was acidified to pH = 5 with conc. HCl and 
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MeOH was removed under reduced pressure. The white 
solid was washed with water and dried. Recrystallization 
was accomplished from EtOH. Yield: 2.42 g (73 %), mp 
235–236° C. 1H NMR (DMSO-d6, 400 MHz) δ 12.87 (1H, 
br s, COOH), 8.40 (2H, s, SO2NH2), 7.85 (2H, d, J = 8.1 
Hz, ArH), 7.36 (2H, d, J = 8.1 Hz, ArH), 3.36 (2H, t, J = 
7.3 Hz, SCH2CH2), 2.95 (2H, t, J = 7.3 Hz, SCH2CH2). 
13C 
NMR (DMSO-d6, 100 MHz) δ 167.57 (CO), 146.85 (C3, 
C5, dd, 1J (19F-13C) = 244.2 Hz, 2J (19F-13C) = 17.1 Hz), 
142.99 (C2, C6, dd, 1J (19F-13C) = 254.0 Hz, 2J (19F-13C) = 
17.1 Hz), 144.79 (Ar), 129.78 (Ar), 129.53 (Ar), 129.28 
(Ar), 122.92 (C4, t, J (19F-13C) = 15.3 Hz), 118.64 (C1, t, J 
(19F-13C) = 20.4 Hz), 35.91 (SCH2CH2), 34.79 (SCH2CH2). 
19F NMR (DMSO-d6, 376 MHz) δ: –133.0 (2F, dd, 
1J = 
24.3 Hz, 2J = 9.9 Hz), –139.1 (2F, dd, 1J = 24.2 Hz, 2J 
= 9.9 Hz). HRMS for C15H11F4NO4S2 [(M-H)
-]: calcd. 
407.9993, found 407.9986.
4-(2-{[4-(Aminosulfonyl)-3-(cyclododecylamino)-
2,5,6-tetrafluorophenyl]thio}ethyl)benzoic acid 
(VR16-09)
The mixture of 4-(2-{[4-(aminosulfonyl)-2,3,5,6-
tetrafluorophenyl]thio}ethyl)benzoic acid (3) (0.40 g, 
0.98 mmol), cyclododecylamine (0.286 g, 1.56 mmol), 
Et3N (0.34 mL, 2.44 mmol), and DMSO (6 mL) was 
stirred at 70° C for 36 h. The solution was cooled to room 
temperature, diluted with water (20 mL) and acidified 
to pH = 5 with 2 M HCl. The white solid was filtered, 
washed with water and dried. Recrystallization was 
accomplished from EtOH:H2O (2:1). Yield: 0.36 g (64 
%), mp 169–170° C. 1H NMR (DMSO-d6, 400 MHz) 
δ 12.86 (1H, br s, COOH), 8.13 (2H, s, SO2NH2), 7.85 
(2H, d, J = 8.1 Hz, ArH), 7.33 (2H, d, J = 8.1 Hz, ArH), 
6.19 (1H, d, J = 9.2 Hz, NH), 3.69 (1H, br s (unresolved 
m), CH of cyclododecane), 3.28 (2H, t, J = 7.3 Hz, 
SCH2CH2), 2.91 (2H, t, J = 7.3 Hz, SCH2CH2), 1.8-1.1 
(22H, m, cyclododecane). 13C NMR (DMSO-d6, 100 
MHz) δ 167.63 (CO), 148.18 (C3, d, J (19F-13C) = 244 
Hz), 144.84 (C6, ddd, 1J (19F-13C) = 249.6 Hz, 2J (19F-13C) 
= 15.6 Hz), 3J (19F-13C) = 3.6 Hz), 144.86 (Ar), 141.62 
(C5, ddd, 1J (19F-13C) = 236.5 Hz, 2J (19F-13C) = 15.3 
Hz, 3J (19F-13C) = 4.6 Hz), 132.81 (C2, d, J (19F-13C) = 
15.1Hz), 129.78 (Ar), 129.57 (Ar), 129.14 (Ar), 119.53 
(C1, dd, 1J (19F-13C) = 11.9 Hz, 2J (19F-13C) = 4.5 Hz), 
117.52 (C4, dd, 1J (19F-13C) = 23.8 Hz, 2J (19F-13C) = 19.1 
Hz), 52.68 (CH of cyclododecane, d, J = 10.6 Hz), 35.85 
(SCH2CH2), 34.73 (SCH2CH2), 30.95 (cyclododecane), 
24.10 (cyclododecane), 23.75 (cyclododecane), 23.40 
(cyclododecane), 23.23 (cyclododecane), 21.28 (cyclo 
dodecane). 19F (DMSO-d6, 376 MHz) δ –120.6 (C3-F, 
d, J = 11.3 Hz), –137.0 (C5-F, dd, 1J = 27 Hz, 2J = 11.5 
Hz), –145.1 (C6-F, dd, 1J = 27 Hz, 2J = 2.5 Hz). HRMS 
for C27H35F3N2O4S2 [(M-H)
-]: calcd. 571.1918, found 
571.1924.
4-(2-{[4-(Aminosulfonyl)-3-(cyclooctylamino)-
2,5,6-tetrafluorophenyl]thio}ethyl)benzoic acid 
(VR16-10)
The mixture of 4-(2-{[4-(aminosulfonyl)-2,3,5,6-
tetrafluorophenyl]thio}ethyl)benzoic acid (3) (0.40 g, 
0.98 mmol), cyclooctylamine (0.214 mL, 1.56 mmol), 
Et3N (0.34 mL, 2.44 mmol), and DMSO (6 mL) was 
stirred at 70° C for 24 h. The solution was cooled to room 
temperature, diluted with water (20 mL) and acidified 
to pH = 5 with 2 M HCl. The white solid was filtered, 
washed with water and dried. Recrystallization was 
accomplished from EtOH:H2O (2:1). Yield: 0.32 g (64 %), 
mp 166–168° C. 1H NMR (DMSO-d6, 400 MHz) δ 12.87 
(1H, br s, COOH), 8.11 (2H, s, SO2NH2), 7.85 (2H, d, J 
= 8.1 Hz, ArH), 7.33 (2H, d, J = 8.1 Hz, ArH), 6.33 (1H, 
d, J = 8.7 Hz, NH), 3.71 (1H, br s (unresolved m), CH of 
cyclooctane), 3.30 (2H, t, J = 7.3 Hz, SCH2CH2), 2.91 (2H, 
t, J = 7.3 Hz, SCH2CH2), 1.9-1.4 (14H, m, cyclooctane). 
13C NMR (DMSO-d6, 100 MHz) δ 167.64 (CO), 148.16 
(C3, d, J (19F-13C) = 242.7 Hz), 144.84 (C6, ddd, 1J 
(19F-13C) = 249.7 Hz, 2J (19F-13C) = 15.7 Hz, 3J (19F-13C) = 
3.8 Hz), 144.9 (Ar), 141.62 (C5, ddd, 1J (19F-13C) = 236.0 
Hz, 2J (19F-13C) = 15.1 Hz, 3J (19F-13C) = 4.4 Hz), 132.21 
(C2, d, J (19F-13C) =14.1 Hz), 129.81 (Ar), 129.53 (Ar), 
129.21 (Ar), 119.41 (C1, dd, 1J (19F-13C) = 11.5 Hz, 2J 
(19F-13C) = 4.9 Hz), 117.51 (C4, dd, 1J (19F-13C) = 23.7 
Hz, 2J (19F-13C) = 18.5 Hz), 55.66 (CH of cyclooctane, d, 
J = 11.4 Hz), 35.86 (SCH2CH2), 34.63 (SCH2CH2), 32.62 
(cyclooctane), 27.29 (cyclooctane), 25.94 (cyclooctane), 
25.53 (cyclooctane), 23.38 (cyclooctane). 19F NMR 
(DMSO-d6, 376MHz) δ –120.81 (C3-F, dd, 
1J = 11.4 Hz, 
2J = 3.1 Hz), –137.1 (C5-F, dd, 1J = 27.0 Hz, 2J = 11.5 
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Hz), –145.2 (C6-F, dd, 1J = 26.9 Hz, 2J = 3.0 Hz). HRMS 
for C23H27F3N2O4S2 [(M-H)
-]: calcd. 515.1292, found 
515.1284.
1-[4-(2-Bromoethyl)phenyl]ethanone (5)
A mixture of AlCl3 (2.91 g, 21.82 mmol), acetyl 
chloride (1.71 mL, 24.05 mmol) and CH2Cl2 (50 mL) was 
stirred at 0° C – +5° C until AlCl3 dissolved. Solution of 
(2-bromoethyl)benzene (4) (2.00 mL, 14.64 mmol) in 
acetyl chloride (3.4 mL) was then added dropwise at 0° C 
– +2° C. The resulting mixture was stirred at 0° C – +2° C 
for 1h and then poured into a mixture of concentrated HCl 
(20 mL) and ice (200 mL). This mixture was extracted 
with CH2Cl2 (30 mL × 3). The combined organic extracts 
were washed with 1N NaOH, water and brine, dried over 
Na2SO4 and concentrated under reduced pressure. The 
resultant residue was subjected to flash chromatography 
(silica gel, hexane/EtOAc, 9:1) to afford compound 5 
(2.83 g, 85 %) as an oil. 1H NMR (400 MHz, DMSO-d6) 
δ 7.94 (2H, d, J = 8.2 Hz, ArH), 7.33 (2H, d, J = 8.2 Hz, 
ArH), 3.61 (2H, t, J = 7.3 Hz, CH2), 3.24 (2H, t, J = 7.3 
Hz, CH2), 2.60 (3H, s, COCH3).
4-(2-Bromoethyl)benzoic acid (6)
A solution of sodium hydroxide (4.16 g, 104 mmol) 
in H2O/dioxane (50 mL/40 mL) was prepared in three-
necked, round bottomed flask fitted with a thermometer 
and a dropping funnel. The solution was cooled to 
0° C in an ice-salt bath, and bromine (2.04 mL, 39.6 
mmol) was slowly added with stirring at 0° C – +7° C. 
1-[4-(2-Bromoethyl)phenyl]ethanone (5) (3.00 g, 13.2 
mmol) was then added dropwise to sodium hypobromite 
solution at 0° C – +2° C. The resulting mixture was 
stirred at 0° C – +5° C for 1.5 h and then acidified with 
concentrated HCl. The precipitated acid was filtered, 
washed with water and dried. Recrystallization was 
accomplished from toluene. Yield: 2.50 g (83 %), mp 207–
208° C, close to the value in the literature mp 205–207° 
C [46]. 1H NMR (400 MHz, DMSO-d6) δ 12.91 (1H, br s, 
COOH), 7.89 (2H, d, J = 8.3 Hz, ArH), 7.41 (2H, d, J = 
8.4 Hz, ArH), 3.78 (2H, t, J = 7.1 Hz, CH2), 3.21 (2H, t, J 
= 7.1 Hz, CH2).
4-(2-Mercaptoethyl)benzoic acid (7)
The mixture of 4-(2-bromoethyl)benzoic acid (6) 
(2.00 g, 8.73 mmol), thiourea (0.80 g, 10.43 mmol), H2O 
(20 mL) was refluxed for 3 h. The solution was cooled to 
room temperature and 10 % (w/v) aqueous NaOH (18 mL) 
was added and the mixture was refluxed again for 1h. The 
solution was then cooled to room temperature, acidified 
to pH = 5 with 2 M HCl and filtered. The white solid 
was washed with water and dried. Recrystallization was 
accomplished from EtOH. Yield: 1.47 g (92 %), mp 157–
159° C, close to the value in the literature mp 156–158° 
C [47]. 1H NMR (400 MHz, DMSO-d6) δ 12.85 (1H, br s, 
COOH), 7.88 (2H, d, J = 8.2 Hz, ArH), 7.36 (2H, d, J = 
8.2 Hz, ArH), 2.92 (2H, t, J = 7.4 Hz, CH2), 2.77 (2H, q, J = 
6.8 Hz, CH2), 2.30 (1H, t, J = 7.7 Hz, SH).
CA inhibition assay
The enzymatic activity of carbonic anhydrase 
isoforms and their inhibition was determined by the 
stopped-flow CO2 hydration assay where the formed acid 
was followed by the absorbance change of a pH indicator. 
The Applied Photophysics SX.18MV-R stopped-flow 
spectrometer was used to measure the absorbance change 
of Phenol-Red pH indicator at 557 nm [49]. Saturated CO2 
solution was prepared by bubbling the CO2 gas in MilliQ 
water at 25° C for 1 h. Experiments were performed at 
25° C using 25 mM Hepes buffer containing 50 mM NaCl 
(pH 7.5), 0–10 μM compound with the final 0.4% (v/v) 
DMSO concentration. The final enzyme concentration was 
10 nM for CA IX and 20 nM for CA XII. Raw curves 
of absorbance change were analyzed using Origin 8.1 
(OriginLab Corporation) and the slope values were used 
to evaluate the rates of CO2 hydration. Spontaneous CO2 
hydration rate was used as a zero value, while the CA 
catalyzed reaction rate - as a maximum value. The Kd 
values were determined using the Morrison equation [50]:
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Fluorescent thermal shift assay
The binding affinity of synthesized compounds to 
recombinant human CAs was measured by the fluorescent 
thermal shift assay (FTSA) where the thermal stabilization 
of the protein by the compound was determined by 
following the fluorescence dependence on temperature 
at various added compound concentrations. The melting 
temperature (Tm) of CA was measured using the Corbett 
Rotor-Gene 6000 instrument (QIAGEN Rotor-Gene Q, 
excitation at 365 ± 20 nm, emission detection at 460 ± 
15 nm). The protein was heated from 25 to 99° C at a 
rate of 1° C/min and the fluorescence change of the 
solvatochromic dye 8-anilino-1-naphthalene sulfonate 
(ANS) was followed. The samples consisted of 5–10 µM 
CA, 0–200 µM ligand, 50 µM ANS, and 50 mM sodium 
phosphate buffer containing 100 mM NaCl at pH 7.0, 
with the final DMSO concentration of 2% (v/v). Protein 
unfolding profiles and the melting temperatures were 
determined at each ligand concentration while recording 
extrinsic fluorescence of ANS. Data analysis was 
performed as previously described [51]. All experiments 
were repeated at least twice. 
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CA IX purification, crystallization and X-ray 
crystallography data collection
Protein was prepared and crystalized as described 
previously [30]. Data were collected at beamline BL14.1, 
Helmholtz-Zentrum Berlin, in Berlin, Germany. Images 
were processed by MOSFLM [52] and reflections 
scaled by SCALA [53]. The structure was determined 
by molecular replacement in MOLREP [54]. The ligand 
parameter files were generated by LIBCHECK [55]. 
Ligand modeling and manual refinement of the structure 
were done in COOT, followed by refinement in REFMAC. 
Data processing, refinement, and validation statistics are 
shown in Supplementary Table 1.
Cell culture
Human cervical (HeLa), lung (H460, A549), breast 
(MDA-MB-231), and pancreatic (AsPC-1) cancer cells 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Lonza) supplemented with 10% fetal bovine 
serum (FBS, Lonza). Cells were exposed to hypoxic 
conditions in the hypoxic chamber (MACS VA500 
microaerophilic workstation, Don Whitley Scientific, UK) 
with 0.2% O2, 5% CO2 and residual N2. Simultaneously, 
normoxic cells were grown in the humidified incubator 
with 21% O2, 5% CO2 at 37° C.
Generating HeLa CA IX knockout cells
HeLa CA IX knockout (KO) clones were 
established as described elsewhere [56]. HeLa 
cells were routinely cultured in DMEM (Lonza) 
supplemented with 10% FBS (Lonza) and transfected 
with a vector containing a CA IX-CRISPR guide RNA 
(CACCGGGGAATCCTCCTGCATCCG) using linear 
polyethylenimine (P-PEI, Polysciences Inc.). 24 h after 
transfection, selection with puromycin was started and 
maintained for 48 h, after which monoclones were picked 
and routinely cultured. After exposure to hypoxia (0.2%, 
24 h), an initial screening for CA IX expression was 
performed by Western blotting (Supplementary Figure 
3), followed by genetic confirmation of CA IX KO in 
clones that showed no CA IX expression. This was done 
by single allele sequencing using the TOPO® TA Cloning® 
Kit (Invitrogen) according to the manufacturer’s protocol. 
KO-causing mutations in the CA9 gene were confirmed in 
two alleles per clone.
Determination of CA catalytic activity in cancer 
cells via gas-analysis mass spectrometry
Catalytic activity of CA in hypoxic MDA-MB-231 
and HeLa cancer cells was determined by monitoring the 
18O depletion of doubly labeled 13C18O2 through several 
hydration and dehydration steps of CO2 and HCO3
- at 24° C 
[57, 58]. The reaction sequence of 18O loss from 13C18O18O 
(m/z = 49) over the intermediate product 13C18O16O (m/z 
= 47) and the end product 13C16O16O (m/z = 45) was 
monitored with a quadrupole mass spectrometer (OmniStar 
GSD 320; Pfeiffer Vacuum, Asslar, Germany). The relative 
18O enrichment was calculated from the measured 45, 47, 
and 49 m/z abundance as a function of time according 
to: log enrichment = log (49×100/(49+47+45)). For the 
calculation of CA activity, the rate of 18O depletion was 
obtained from the linear slope of the log enrichment over 
the time, using OriginPro 8.6 (OriginLab Corporation). 
The rate was compared with the corresponding rate of the 
non-catalyzed reaction. Enzyme activity in units (U) was 
calculated from these two values as defined by Badger and 
Price [59]. From this definition, one unit corresponds to 
100% stimulation of the non-catalyzed 18O depletion of 
doubly labeled 13C18O2. MDA-MB-231 cells were cultured 
in Gibco Leibovitz-L15 medium (Life Technologies 
GmbH, Darmstadt, Germany), supplemented with 
10% fetal calf serum, 5 mM glucose and 1% penicillin/
streptomycin, pH 7.4. HeLa cells were cultured in RPMI-
1640 Medium (Sigma Aldrich, Schnelldorf, Germany), 
supplemented with 10% fetal calf serum and 1% penicillin 
/ streptomycin. Both cell lines were cultured under hypoxia 
(1% O2) for 3 days prior to measurements. Cells were 
trypsinized, washed and resuspended in HEPES-buffered 
saline (143 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgSO4, 1 mM Na2HPO4, 10 mM HEPES, pH 7.2). For 
determination of IC50 values, 2 cell culture plates (58 
cm2), grown to 80% confluency, were used for every 
single measurement. To ensure an equal amount of cells 
within one set of measurements, cells from several plates 
were pooled and then aliquoted according to the number 
of tested inhibitor concentrations. For the determination 
of IC50, the cell suspensions were incubated in the 
corresponding concentration of inhibitor for up to 3 h. 
For every measurement, the non-catalyzed reaction was 
determined for 6 min in the presence of inhibitor, before 
cell suspension was added to the measuring cuvette and the 
catalyzed reaction was determined for 8 min. CA activity 
in the presence of inhibitor was normalized to the activity 
in the absence of inhibitor. IC50 values were determined 
by Hill equation using OriginPro 8.6. To investigate 
specificity of the inhibitors in HeLa WT and HeLa CA IX 
KO cells, the non-catalyzed reaction was determined for 6 
min in the absence of inhibitor, before a suspension of 5 
× 106 cells was added to the measuring cuvette. After the 
catalyzed reaction was determined for 6 min, the inhibitor 
was added to the cuvette and the reaction was determined 
for another 6 min.
Extracellular acidification (pH) assay
HeLa, H460, MDA-MB-231, and AsPC-1 cells were 
cultured in DMEM (Lonza) supplemented with 10% FBS 
(Lonza), whereas A549 cells were grown in-house made 
analogous medium differing only by a lower amount of 
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sodium bicarbonate (final concentration 10 mM). Cell 
densities for each cell line were optimized to get ~100% 
confluence at the end of experiment under normoxic 
and hypoxic (0.2% O2) conditions upon vehicle (0.05% 
DMSO) treatment. Such conditions were necessary to 
obtain the highest possible level of CA IX-dependent 
extracellular acidification. Cells were plated in 6 cm 
dishes and allowed to attach overnight in normoxia. The 
next day cells were exposed to 5–50 µM doses of each 
inhibitor or DMSO for 72 h in parallel under normoxic 
or hypoxic conditions and pH of the culture medium was 
measured at the end of each experiment as previously 
reported [33]. Results are shown as a difference between 
the pH of medium in the control plate (without seeded 
cells) and the pH of medium in the targeted plate (cells 
exposed to the compound or vehicle).
Cell viability assay
Cytotoxicity of inhibitors was determined by the 
alamarBlue® cell viability assay (Life Technologies). Cell 
densities for HeLa, H460, MDA-MB-231, A549, and 
AsPC1 were optimized to get ~80% confluence at the 
end of experiment under normoxic and hypoxic (0.2% 
O2) conditions upon vehicle (0.25% DMSO) treatment. 
Briefly, cells were seeded in 96-well plates and allowed to 
attach overnight in normoxia. On the next day, cells were 
exposed to normoxia or hypoxia and medium was replaced 
with pre-incubated normoxic or hypoxic medium with 
final concentrations of 10–150 µM of inhibitor or DMSO. 
After 72 h, cells were incubated with 10% alamarBlue® 
for 2 h under normoxia at 37° C. The fluorescence 
signal was measured using the multi-mode microplate 
reader (FLUOstar® Omega, BMG Labtech) at 580 nm 
(excitation wavelength 540 nm). Response to treatments 
was quantified by evaluating EC50 values (concentration 
of inhibitor that leads to half-maximum viability response 
determined by Hill fit).
Clonogenic cell survival assays
Clonogenic survival of HeLa cell monolayers was 
evaluated using cell densities applied in the extracellular 
acidification assay to determine the effect of inhibitors 
on the clonogenic cell survival while having the same 
acidification conditions. Cells were exposed to 10–50 µM 
VR16-09, VD11-4-2, VD12-09, or 0.25% DMSO for 72 
h upon normoxic or hypoxic conditions (0.2% O2). Such 
doses of inhibitors significantly reduced hypoxia-induced 
acidification. Then cells were trypsinized, reseeded in 
triplicate with known cell densities and allowed to form 
colonies for 14 days. To test inhibitors in 3D cell models, 
non-hypoxic and hypoxic H460 spheroids were exposed to 
5–15 µM doses of VR16-09 or 0.25% DMSO for 24 h on 
day 4 or day 11, respectively. Single cell suspensions were 
prepared and cells were plated in triplicate with known 
cell densities and allowed to form colonies for 14 days. 
Colonies were quantified after staining and fixation with 
0.4% methylene blue in 70% ethanol. Surviving fraction 
was normalized to vehicle (DMSO).
Spheroid growth 
To prepare plates for the growth of attachment-
free H460 spheroids, autoclaved 1.5% w/v agarose 
(Sigma-Aldrich) was dispensed in the inner 60 wells of 
96-well plates (50 µL/well) and left for polymerization at 
room temperature for 30 min. H460 cells were plated in 
modified 96-well plates to the surface of agarose menisci 
with a density of 500 cells/well. The DMEM was refreshed 
every two days. After 7 or 11 days in culture, spheroids 
were incubated with 20 µg/mL pimonidazole (PIMO, 
Hypoxyprobe-1, HP-1000, BioConnect) for 2 h at 37° 
C, collected and cryoconserved for immunofluorescence 
analysis (see below). In parallel 4 or 11 days after cell 
seeding, spheroids of homogeneous volume were treated 
with 5–15 µM VR16-09 or 0.25% DMSO for 24 h and 
collected for clonogenic survival assay.
Western blot
Protein isolates were prepared by incubating scraped 
cells in RIPA buffer on ice for 30 min, followed by 
centrifugation to remove cell debris. Protein concentrations 
were determined using Bradford protein quantification 
reagent (BioRad). Western blot was performed using 
primary antibodies, including mouse anti-CA IX (M75, 
1:40, kindly provided by Silvia Pastorekova, Institute of 
Virology, Slovak Academy of Science, Slovak Republic), 
mouse anti-CA XII (clone 15A4, 1:100, kindly provided 
by Aurelija Žvirblienė, Institute of Biotechnology, Vilnius 
University, Lithuania), rabbit anti-MCT1 (1:100), rabbit 
anti-MCT4 (1:400, kindly provided by Holger M. Becker, 
University of Veterinary Medicine Hannover, Hannover, 
Germany), rabbit anti-lamin A (1:10.000, Sigma-Aldrich), 
and mouse anti-actin (1:2.000.000, MP Biomedicals). 
Primary antibodies were incubated overnight at 4° 
C, whereas horseradish peroxidase-linked secondary 
antibodies (1:2.000, Cell Signaling) were incubated for 1 
h at room temperature. Amersham ECL Western Blotting 
Detection Reagent (GE Healthcare Life Sciences) was 
applied for the detection of CA XII, MCT1, MCT4, 
and lamin A, while SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate (Life Technologies) was used 
for the visualization of CA IX and actin.
Immunofluorescence analysis
H460 spheroids of day 7 and day 11 were 
cryoconserved. Frozen sections (7 µm) of spheroids were 
fixed in acetone (4° C, 10 min), air-dried and rehydrated 
in phosphate buffered saline (PBS). Non-specific binding 
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was blocked by incubation with 0.5% goat serum in PBS 
for 30 min at room temperature. Sections were stained 
(37° C, 1 h) using primary rabbit anti-PIMO (1:250) or 
mouse anti-CA IX (1:100, M75), followed by incubation 
(37° C, 1 h) with secondary goat anti-rabbit Alexa488 
or goat anti-mouse Alexa594, respectively (both 1:500, 
from Invitrogen). Nuclei were stained with DAPI (final 
concentration 5 µg/mL) for 2 min at room temperature. 
Staining without primary antibody was used as negative 
control. Sections were viewed at 10× magnification by 
Nikon Eclipse E800 microscope (Nikon Instruments Inc.).
Statistics
Statistical analysis was performed using GraphPad 
Prism (version 6.01). A non-parametric Mann-Whitney U 
test for small groups was applied to evaluate the statistical 
significance of differences between two independent 
groups of variables and p < 0.05 was assumed to be 
significant (*p < 0.05; **p < 0.01, ***p < 0.001, ****p < 
0.0001).
CONCLUSIONS
In conclusion, the integrative set of synthesis, 
inhibitory activities, biophysical binding profiles, 
crystallographic analysis, and effects in 2D and 3D cancer 
cell culture models is described in the present study. 
X-ray analysis demonstrated novel, previously unseen 
conformational changes in CA IX active site due to ligand 
binding. Our compounds exhibited high affinity and 
selectivity towards recombinant CA IX, reached nanomolar 
CA IX-dependent functional effects as well reduced hypoxia-
induced acidification in a variety of cancer cell lines. 
Interestingly, hypoxia-dependent reduction of clonogenic 
survival was only observed in spheroids, highlighting the 
importance of investigating CA IX-targeting compounds in 
3D cell models resembling the naturally occurring hypoxic 
microenvironment with clonogenic survival as endpoint. The 
newly designed compounds are therefore promising agents 
for CA IX-specific therapy.
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